X4 Pharmaceuticals Inc (NASDAQ:XFOR) Q1 2024 Results Conference Call May 7, 2024 8:30 AM ET

Company Participants

Dan Ferry - IR
Paula Ragan - CEO
Adam Mostafa - CFO
Christophe Arbet-Engels - COO
Mark Baldry - CMO

Conference Call Participants

Stephen Willey - Stifel
Edward Tenthoff - Piper Sandler
Kristen Kluska - Cantor Fitzgerald
Swayampakula Ramakanth - H.C. Wainwright
David Bautz - Zacks Small Cap Research

Operator

[Indiscernible] X4 Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded.

It's now my pleasure to introduce your host, Mr. Dan Ferry from LifeSci Advisors. Thank you, Mr. Ferry. You may begin.

Dan Ferry

Thank you, operator, and good morning everyone. Thank you for joining us today. Presenting on today’s call will be Dr. Paula Ragan; X4’s President and Chief Executive Officer, and company’s Chief Financial Officer, Adam Mostafa. Following prepared remarks, we will open the call to your questions and we’ll be joined by Chief Commercial Officer, Mark Baldry; Chief Medical Officer, Dr. Christophe Arbet-Engels; Chief Operating Officer, Mary DiBiase; and Chief Scientific Officer, Art Taveras; and Jose Juves. Head of Corporate & Patient Affairs

As a reminder, on today’s call, the company will be making forward-looking statements regarding regulatory and product development and commercialization plans, as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Description of these risks can be found in X4’s most recent filings with the SEC, including this year’s Form 10-K, which was filed on March 21, 2024, and in the company's Form 10-Q, which is expected to be filed later today.

I'll now turn it over to Paula Ragan.

Paula?

Paula Ragan

Thanks so much, Dan, and welcome everyone. Following last week's approval of XOLREMDI, it's exciting to reiterate today why this critical regulatory achievement represents a significant opportunity to improve the lives of WHIM patients and offers a strong platform for the company's growth. More specifically, I'll touch on our plans for expanding XOLREMDI's use in WHIM geographically and for quickly advancing into a potential larger indication chronic neutropenia. But let's start with last Monday's transformative announcement.

As you know, XOLREMDI or Mavorixafor is now approved by the FDA for use in the US in patients 12 years of age and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.